ID: ALA5180732

Max Phase: Preclinical

Molecular Formula: C189H296N50O56S

Molecular Weight: 4196.81

Associated Items:

Representations

Canonical SMILES:  CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCNC(=O)CC[C@H](N)C(=O)O)C(N)=O)[C@@H](C)O)C(C)C)C(=O)O)C(=O)O

Standard InChI:  InChI=1S/C189H296N50O56S/c1-17-18-19-20-21-22-23-24-25-26-27-28-35-57-144(252)211-125(183(292)293)67-73-145(253)212-124(182(290)291)66-72-143(251)204-77-43-40-54-117(216-169(276)133(89-147(255)256)227-175(282)137(96-241)231-180(287)153(104(11)244)236-172(279)130(84-106-48-33-30-34-49-106)229-178(285)151(102(9)242)234-146(254)94-208-157(264)120(63-68-138(193)246)233-184(294)188(12,13)238-156(263)113(192)87-109-93-202-97-209-109)160(267)230-136(95-240)174(281)217-116(53-38-41-75-190)159(266)222-128(85-107-58-60-110(245)61-59-107)167(274)220-127(82-99(4)5)166(273)228-135(91-149(259)260)176(283)239-189(14,15)185(295)232-119(56-45-79-206-187(200)201)161(268)215-118(55-44-78-205-186(198)199)158(265)210-101(8)155(262)214-121(64-69-139(194)247)162(269)226-134(90-148(257)258)170(277)223-129(83-105-46-31-29-32-47-105)171(278)235-150(100(6)7)177(284)219-122(65-70-140(195)248)163(270)224-131(86-108-92-207-114-51-37-36-50-111(108)114)168(275)221-126(81-98(2)3)165(272)218-123(74-80-296-16)164(271)225-132(88-141(196)249)173(280)237-152(103(10)243)179(286)213-115(154(197)261)52-39-42-76-203-142(250)71-62-112(191)181(288)289/h29-34,36-37,46-51,58-61,92-93,97-104,112-113,115-137,150-153,207,240-245H,17-28,35,38-45,52-57,62-91,94-96,190-192H2,1-16H3,(H2,193,246)(H2,194,247)(H2,195,248)(H2,196,249)(H2,197,261)(H,202,209)(H,203,250)(H,204,251)(H,208,264)(H,210,265)(H,211,252)(H,212,253)(H,213,286)(H,214,262)(H,215,268)(H,216,276)(H,217,281)(H,218,272)(H,219,284)(H,220,274)(H,221,275)(H,222,266)(H,223,277)(H,224,270)(H,225,271)(H,226,269)(H,227,282)(H,228,273)(H,229,285)(H,230,267)(H,231,287)(H,232,295)(H,233,294)(H,234,254)(H,235,278)(H,236,279)(H,237,280)(H,238,263)(H,239,283)(H,255,256)(H,257,258)(H,259,260)(H,288,289)(H,290,291)(H,292,293)(H4,198,199,205)(H4,200,201,206)/t101-,102+,103+,104+,112-,113-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,150-,151-,152-,153-/m0/s1

Standard InChI Key:  RRZMQQCYMZLEDK-FNJHLGSQSA-N

Associated Targets(Human)

Glucagon receptor 2563 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Glucagon-like peptide 1 receptor 111429 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 4196.81Molecular Weight (Monoisotopic): 4194.1572AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Palani A, Nawrocki AR, Orvieto F, Bianchi E, Mandić E, Pessi A, Huang C, Deng Q, Toussaint N, Walsh E, Reddy V, Ashley E, He H, Mumick S, Hawes B, Marsh D, Erion M, Nargund R, Carrington PE..  (2022)  Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes.,  13  (8.0): [PMID:35978682] [10.1021/acsmedchemlett.2c00217]

Source